27 results
Thumbnail

D2.426 - Polarization of PBMCs during SARS-CoV-2 Infections

Thumbnail

D2.432 - Therapeutic Efficacy of Platelet-Rich Plasma in Androgenic Alopecia: A Meta-Analysis of Single Versus Double-Blinded Randomized Controlled Trials

Thumbnail

D2.423 - Changes in the expression of regulatory receptors on CD8+ T cytotoxic lymphocytes as a marker of the risk of developing a post COVID-19 condition in patients after a severe course of COVID-19

Thumbnail

D2.425 - Type 2 neuro-immune signaling is upregulated in Candida albicans-driven itch

Thumbnail

D2.427 - Inhibition of the IL-17 pathway in the treatment of systemic vasculitis: molecular biology and case review

Thumbnail

D2.428 - Contribution of Allelic Gene Variants of the Indoleamine-2,3-Dioxygenase and Dectin-1 to the Risk of Invasive Aspergillosis in Oncohematological Patients

Thumbnail

D2.429 - Virus-Specific Regulatory T-Cell Dysregulation in Post-COVID-19 and EBV-Associated Vasculitis

Thumbnail

D2.430 - Automated 24-Hour Quantification of Scratching Behavior Reveals Distinct Physiological and Allergic Pruritus Signatures in Mice

Thumbnail

D2.433 - Clinical and Oxidative Function Profiles in Heterozygous Female Carriers of X-Linked Chronic Granulomatous Disease

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut